Changes in prostate-specific antigen kinetics during androgen-deprivation therapy as a predictor of response to abiraterone in chemonaïve patients with metastatic castration-resistant prostate cancer

PURPOSE: Metastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis. Abiraterone acetate (AA), enzalutamide, and chemotherapy are first-line treatments for patients with mCRPC. This study examined prognostic factors for AA response in the form of prostate-specific antigen (PSA) kin...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Chung-Lin, Chang, Ying-Hsu, Liu, Chung-Yi, Hsieh, Ming-Li, Huang, Liang-Kang, Chu, Yuan-Cheng, Kan, Hung-Cheng, Lin, Po-Hung, Yu, Kai-Jie, Chuang, Cheng-Keng, Wu, Chun-Te, Pang, See-Tong, Shao, I-Hung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Urological Association 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448667/
https://www.ncbi.nlm.nih.gov/pubmed/36068000
http://dx.doi.org/10.4111/icu.20210450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448667/
https://www.ncbi.nlm.nih.gov/pubmed/36068000
http://dx.doi.org/10.4111/icu.20210450

Ejemplares similares